Display options
Cite
Naito T, Tanaka Y, Hino M, et al. A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. Respir Med Case Rep. 2017;21:62-65doi: 10.1016/j.rmcr.2017.03.021.
Naito, T., Tanaka, Y., Hino, M., & Gemma, A. (2017). A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. Respiratory medicine case reports, 2162-65. https://doi.org/10.1016/j.rmcr.2017.03.021
Naito, Tomoyuki, et al. "A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy." Respiratory medicine case reports vol. 21 (2017): 62-65. doi: https://doi.org/10.1016/j.rmcr.2017.03.021
Naito T, Tanaka Y, Hino M, Gemma A. A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. Respir Med Case Rep. 2017 Mar 29;21:62-65. doi: 10.1016/j.rmcr.2017.03.021. eCollection 2017. PMID: 28393009; PMCID: PMC5377439.
Copy Download .nbib Format: NLM
Share it on

Respir Med Case Rep. 2017 Mar 29;21:62-65. doi: 10.1016/j.rmcr.2017.03.021. eCollection 2017.

A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy.

Respiratory medicine case reports

Tomoyuki Naito, Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma

Affiliations

  1. Respiratory Disease Center, Chiba Hokusoh Hospital, Nippon Medical School, Chiba, Japan.
  2. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

PMID: 28393009 PMCID: PMC5377439 DOI: 10.1016/j.rmcr.2017.03.021

Abstract

A 72-year-old woman was admitted to our hospital and was diagnosed with interstitial pneumonia (IP) associated with amyopathic dermatomyositis (ADM). The patient experienced three acute IP exacerbations in the 7 years that followed, which were each treated and resolved with steroid pulse therapy. The patient was closely examined for respiratory failure with right heart catheterization (RHC), which demonstrated that she had a mean pulmonary artery pressure (mPAP) of 34 mmHg. The patient was thus diagnosed as having pulmonary hypertension (PH) associated with anti-synthetase syndrome (ASS) and was started on bosentan therapy, which led to improvements in mPAP as well as in subjective symptoms over time. Indeed, she had had no acute exacerbations with serum markers of IP remaining low over 6 years following initiation of bosentan therapy, suggesting that bosentan may have a role in controlling IP. In addition, she was confirmed to be anti-ARS antibody-positive after 5 years of bosentan therapy, when anti-aminoacyl tRNA synthetase (anti-ARS) antibody testing became available.

Keywords: ADM, amyopathic dermatomyositis; ASS, anti-synthetase syndrome; Bosentan; CVD, collagen-vascular disease; Collagen-vascular disease; Endothelin antagonist; IP, interstitial pneumonia; Interstitial pneumonia; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PM, polymyositis; Pulmonary hypertension; TR, tricuspid regurgitation

References

  1. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41 - PubMed
  2. Eur Respir J. 2013 Nov;42(5):1271-82 - PubMed
  3. Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9 - PubMed
  4. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19 - PubMed
  5. Rheum Dis Clin North Am. 1994 Nov;20(4):857-80 - PubMed
  6. Medicine (Baltimore). 1991 Nov;70(6):360-74 - PubMed
  7. Q J Med. 1990 Oct;77(282):1019-38 - PubMed
  8. Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-17 - PubMed
  9. Arthritis Rheum. 1992 Apr;35(4):449-56 - PubMed

Publication Types